NCT06622057
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
Recruiting
PHASE3Ages 18+InterventionalTreatmentInnoPharmax Inc.
~240 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:D07001-Softgel CapsulesPlaceboCapecitabine
At a glance
Recruiting sites
3 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Survival (OS)
Measured over From date of randomization until the date of death, assessed up to 2 years
Conditions
Where it's being run
4 sites across 4 statesArizona1
Florida1
Ohio1
Taiwan1
Study leadership
- Criss Cheng · STUDY_DIRECTOR · InnoPharmax Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Overall Survival (OS)From date of randomization until the date of death, assessed up to 2 years
To assess the over survival (OS) of 2 doses of D07001-softgel capsules + capecitabine compared with placebo + capecitabine